Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules

Curr Opin Mol Ther. 2004 Apr;6(2):160-5.

Abstract

Ii protein suppression is a promising antisense drug-based therapy that dramatically enhances the immunogenicity of tumor cell major histocompatibility complex class II-presented antigenic epitopes. The strength of this approach is that the antisense only needs to be transiently effective in a fraction of the tumor cells. The systemic antitumor immune response generated subsequently eradicates both directly treated cells and distant tumor deposits. The drugs and mechanisms of this therapy are considered, in addition to practical developmental questions.

MeSH terms

  • Animals
  • Antigen-Presenting Cells / immunology
  • Antigens, Differentiation, B-Lymphocyte / genetics
  • Antigens, Differentiation, B-Lymphocyte / immunology*
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology
  • Clinical Trials as Topic
  • Genes, MHC Class II
  • Genetic Therapy / methods*
  • Histocompatibility Antigens Class II / genetics
  • Histocompatibility Antigens Class II / immunology*
  • Humans
  • Immunotherapy / methods*
  • Mice
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Oligonucleotides, Antisense / therapeutic use*

Substances

  • Antigens, Differentiation, B-Lymphocyte
  • Antigens, Neoplasm
  • Histocompatibility Antigens Class II
  • Oligonucleotides, Antisense
  • invariant chain